Skyscape Web Viewer : Cancer Pharmacology: An Illustrated Manual of Anticancer Drugs : Main Index

View All
ALL
all-trans retinoic acid (ATRA) Answer 8.2 Question 8.1 Differentiating Agents and Microenvironment
American Society of Clinical Oncology (ASCO)
AML
anaplastic lymphoma kinase (ALK) Targeted Therapies (Small Molecules) Anaplastic Lymphoma Kinase (ALK) Fusion
and rogen deprivation therapy (ADT) Male Hormonal Therapies Question 10.2 Overview of Prostate Cancer (PC) Progression and Treatment
and rogen receptor (AR) Molecular Mechanism of and rogen Receptor (AR) Activation by Dihydrotestosterone (DHT) Male Hormonal Therapies Physiological and Anatomical Targets of FDA-Approved "Hormonal" Drugs for Prostate Cancer
and rogen response element (ARE)
antibody-dependent cell-mediated cytotoxicity (ADCC) Naked Monoclonal Antibody Mechanism of Action Components of 90y-Ibritumomab Tiuxetan Novel Therapeutic Strategies in Oncology
antibody-dependent cellular cytotoxicity (ADCC)
antibody-drug conjugates (ADC) Monoclonal Antibodies Including Immunoconjugates and Cytokine-Directed Agents Multiple Myeloma as a Paradigm for Multi-Targeted Intervention
Anticancer drug development limitations to effective action pathophysiology of cancer targets usefulness work at all, stop working, or never work? overview pharmacokinetics treatment goal usefulness\|Kaplan-meier method, survival in the two groups
Antifolates action mechanism folate transporters absorption and elimination adverse events overview toxicity and rescue relative affinities of folate receptor (FR) and reduced folate carrier (RFC) toxicity and rescue\|leucovorin (LV) "rescue" in high-dose MTX toxicity and rescue\|THF compared to leucovorin (folinic acid, LV) structure treatment goal toxicity and rescue\|MTX breakdown via glucarpidase toxicity and rescue\|urinary excretion of high-dose MTX and effect of medications and urine pH
ALT
aminotransferase (AST)
ANC
antibody-dependent cellular phagocytosis (ADCP)
Antimetabolites classification treatment goal overview
Antimitotics chromosome cycle ixabepilone microtubules treatment goal adverse events related to vinca alkaloids eribulin microtubule-directed agents taxanes, adverse events vinca alkaloids and neurotoxicity
Antivascular endothelial growth factor
APL
Apoptosis therapeutic activation BH3 mimetics
a proliferation-inducing ligand (APRIL)
ara-C
ara-CMP
ARDS
area under the plasma drug concentration-time curve (AUC) Pharmacokinetics: Relation to Toxicity or Achievement of Steady State Transplant-Related Agents
aromatase inhibitors (AIs)
arsenic trioxide (ATO) Differentiating Agents and Microenvironment Answer 8.2 Question 8.2
ASCO